What triggered Injective latest price pullback

Traders Union
All News
Crypto News
Injective slides 10.95% today to $3.56

Highlights

Injective approved a network upgrade, while Pineapple Financial accumulated $2 million in INJ and earmarked $20.79 million for further purchases.
Injective executed a community buyback and burned approximately 54,999 INJ, reducing token supply and enhancing ecosystem scalability and DeFi capabilities.
INJ trades at $3.56 above the MA-20 ($3.25) but below the MA-50 ($4.19), with projected downside toward $2.66–$2.82 and sub-20% upside probability short term.

Supply reduction drives governance progress as major buyers accumulate

Injective approved a network upgrade, accompanied by ongoing accumulation from key participants such as Pineapple Financial, which recently purchased $2 million in INJ and reserved $20.79 million for further acquisition. The platform also completed a community buyback and permanent burn of approximately 54,999 INJ, reducing overall token supply. These actions underscore continued governance progress and ecosystem enhancements to advance scalability and DeFi capabilities.

Anton Kharitonov, expert at Traders Union, sees the current INJ structure as technically fragile. He notes the price sits below both MA-50 and MA-200, exposing weakness in broader trend signals. Kharitonov is wary of momentum divergences and the recent session’s 10.95% drop, calling out the high volatility as a risk rather than opportunity. He points to the strong sell signal from MACD and overbought oscillators as warning signs of exhaustion. "Despite governance improvements and token burns, I remain cautious as downside potential below $3.25 remains significant."

Viktoras Karapetjanc, expert at Traders Union, views Injective’s governance actions and institutional interest as strong positive catalysts. He believes Pineapple Financial’s accumulation and the ongoing supply reduction reinforce confidence in future DeFi growth. Karapetjanc emphasizes that fundamental progress supports resilience, even if price consolidates short-term. "Buybacks, strategic upgrades, and major acquisitions show that the bullish structure remains intact for further growth ahead."

Parshwa Turakhiya, analyst, highlights that market sentiment is conflicted as buyers show strength but price action turns bearish. He notes the strong ADX trend and RSI edge but warns the downside gap and daily drop have shifted short-term bias. Turakhiya sees a volatile window where oversold pullbacks may offer tactical trades if support at $3.25 holds. "I see quick intraday swings presenting sentiment-driven setups, so capital protection and flexibility are key here."

Downside volatility rises as momentum signals diverge after selloff

Momentum signals offer a mixed picture: while D1 ADX at 37.45 signals a strong trend and the RSI (55.99) suggests buyers still have an edge, MACD D1 gives a strong sell. Stoch RSI and CCI both indicate overbought conditions, while BBP also points to prevailing buying interest but warns of waning buyer strength intraday. The Awesome Oscillator remains neutral and does not actively confirm the prevailing direction. INJ opened at $3.77 after a previous close of $4.00, showing a small downside gap, and the price now trades near the session low following a daily drop of 10.95%. Intraday volatility is high after a sharp move lower, and the tone reflects clear pressure after the open. Divergences between momentum and oscillators highlight indecision, as bearish daily moves contradict some otherwise bullish momentum signals.

Previously it was reported that Injective is exhibiting short-term bullish momentum above its 20-day moving average, but remains below key longer-term averages within a broader bearish trend. Despite recent institutional support and network upgrades lifting sentiment, conflicting momentum and overbought signals suggest limited upside, with price expected to remain rangebound between support near $3.30 and resistance at $3.95.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.